<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Summary of recommendations from expert groups for follow-up surveillance after resection of a well-differentiated gastroenteropancreatic neuroendocrine tumor</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Summary of recommendations from expert groups for follow-up surveillance after resection of a well-differentiated gastroenteropancreatic neuroendocrine tumor</h1>
<div class="graphic"><div class="figure"><div class="ttl">Summary of recommendations from expert groups for follow-up surveillance after resection of a well-differentiated gastroenteropancreatic neuroendocrine tumor</div><div class="cntnt"><table cellspacing="0"><colgroup width="10%"></colgroup><colgroup span="3" width="30%"></colgroup> <tbody> <tr> <td class="subtitle1">Organization</td> <td class="subtitle1">Recommendations for SBNET</td> <td class="subtitle1">Recommendations for panNET</td> <td class="subtitle1">Groups not requiring follow-up</td> </tr> <tr class="divider_bottom"> <td>NCCN<sup>[1]</sup></td> <td>Clinical review at 3 to 12 months with biomarkers and CT or MRI as clinically indicated; then review every 6 to 12 months for maximum of 10 years.</td> <td>Clinical review at 3 to 12 months with biomarkers and CT or MRI as clinically indicated; then review every 6 to 12 months for maximum of 10 years.</td> <td>Appendiceal NET &lt;2 cm completely resected by appendicectomy "as clinically indicated"; rectal NET &lt;1 cm with negative margins.</td> </tr> <tr class="divider_bottom"> <td>ENETS<sup>[2,3]</sup></td> <td> <p>Grade 1: US, CT, or MRI at 6 and 12 months, then yearly or longer; octreoscan (or gallium-68-based PET) at baseline and every 2 years.</p> Grade 2-3: US, CT, or MRI every 3 months indefinitely; octreoscan (or gallium-68-based PET) at 3 months and yearly. </td> <td> <p>Grade 1: US, CT, or MRI at 6 and 12 months, then yearly or longer; octreoscan (or gallium-68-based PET) at baseline and every 2 years.</p> Grades 2-3: US, CT, or MRI every 3 months indefinitely; octreoscan (or gallium-68-based PET) at 3 months and yearly. </td> <td>Appendiceal NET &lt;1 cm completely resected by appendicectomy; appendiceal NET &gt;1 cm completely resected by right hemicolectomy without LN involvement; completely resected rectal NETs &lt;1 cm.</td> </tr> <tr class="divider_bottom"> <td>ESMO<sup>[4]</sup></td> <td> <p>Grades 1-2: Biochemistry and CT or MRI every 3 to 6 months.</p> Grade 3: Every 2 to 3 months. Octreoscan after 18 to 24 months if SRS positive. </td> <td> <p>Grades 1-2: Biochemistry and CT or MRI every 3 to 6 months.</p> Grade 3: Every 2 to 3 months. Octreoscan after 18 to 24 months if SSTR positive. </td> <td>Not listed.</td> </tr> <tr class="divider_bottom"> <td>NANETS<sup>[5,6]</sup></td> <td>Stages I-III: Long-term surveillance (at least 10 years); imaging every 6 months transitioning to annual imaging over time. No routine SSTR imaging required.</td> <td>CT or MRI 3 to 6 months after resection, then every 6 to 12 months for at least 7 years. Consider CgA or hormone markers if elevated levels at baseline, and nuclear imaging for suspected recurrence.</td> <td>Stage I rectal NETs.</td> </tr> <tr> <td>CommNETs</td> <td>Grade 1: CT every 12 months for 3 years, then every 1 to 2 years for total of at least 10 years; no biochemistry.</td> <td>Grade 1: CT every 12 months for 3 years, then every 1 to 2 years for 10 years; no biochemistry.</td> <td>Midgut: Incidental grade 1, stage I tumors; pancreas: grade 1, node-negative, &lt;2 cm tumors; rectal: grade 1, node-negative, T1 tumors; appendix: grade 1, &lt;1 cm tumors.</td> </tr> </tbody></table></div><div class="graphic_footnotes">NET: neuroendocrine tumor; SBNET: small bowel NET; panNET: pancreatic NET; NCCN: National Comprehensive Cancer Network; CT: computed tomography; MRI: magnetic resonance imaging; ENETS: European Neuroendocrine Tumor Society; US: ultrasound; PET: positron emission tomography; LN: lymph node; ESMO: European Society for Medical Oncology; SRS: somatostatin receptor scintigraphy; SSTR: somatostatin receptor; NANETS: North American Neuroendocrine Tumor Society; CgA: chromogranin A; CommNETs: Commonwealth Neuroendocrine Tumour Collaboration.</div><div class="graphic_reference">Reproduced with permission from: Singh S, Moody L, Chan DL, et al. Follow-up Recommendations for Completely Resected Gastroenteropancreatic Neuroendocrine Tumors. JAMA Oncol 2018; 4(11):1597-1604. Copyright © 2018 American Medical Association. All rights reserved.<br/><ol>
<li>​Dasari A, Shen C, Halperin D, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol 2017; 3:1335.</li>
<li>Hallet J, Law CHL, Cukier M, et al. Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes. Cancer 2015; 121:589.</li>
<li>Pape U-F, Niederle B, Costa F, et al; Vienna Consensus Conference participants. ENETS consensus guidelines for neuroendocrine neoplasms of the appendix (excluding goblet cell carcinomas). Neuroendocrinology 2016; 103:144.</li>
<li>Meyerhardt JA, Mangu PB, Flynn PJ, et al; American Society of Clinical Oncology. Follow-up care, surveillance protocol, and secondary prevention measures for survivors of colorectal cancer: American Society of Clinical Oncology clinical practice guideline endorsement. J Clin Oncol 2013; 31:4465.</li>
<li>Kunz PL, Reidy-Lagunes D, Anthony LB, et al; North American Neuroendocrine Tumor Society. Consensus guidelines for the management and treatment of neuroendocrine tumors. Pancreas 2013; 42:557.</li>
<li>Strosberg JR, Halfdanarson TR, Bellizzi AM, et al. The North American Neuroendocrine Tumor Society consensus guidelines for surveillance and medical management of midgut neuroendocrine tumors. Pancreas 2017; 46:707.</li></ol></div><div id="graphicVersion">Graphic 129110 Version 10.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
